期刊
CLINICAL MEDICINE
卷 17, 期 5, 页码 439-443出版社
ROY COLL PHYS LONDON EDITORIAL OFFICE
DOI: 10.7861/clinmedicine.17-5-439
关键词
Acute respiratory distress syndrome; acute respiratory failure; ARDS; critical illness; ventilator-associated lung injury
资金
- GSK
- Pfizer
- BI
- Peptinnovate
- Silence Therapeutics
- Cell Catapult
Acute respiratory distress syndrome is a common cause of acute respiratory failure that is underdiagnosed both inside and outside of intensive care units. Progression to the most severe forms of the syndrome confers a mortality rate greater than 40% and is associated with often severe functional disability and psychological sequelae in survivors. While there are no disease-modifying pharmacotherapies for the syndrome, this progression may be prevented through the institution of quality improvement measures that minimise iatrogenic injury associated with acute severe illness.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据